1. Attarwala AA, Hardiansyah D, Romano C, Roscher M, Molina-Duran F, Wängler B, Glatting G. A Method for Point Spread Function Estimation for Accurate Quantitative Imaging. IEEE Trans Nucl Sci 2018; 65: 961-9.
  2. Baum RP, Kulkarni HR, Singh A, Kaemmerer D, Mueller D, Prasad V, Hommann M, Robiller FC, Niepsch K, Franz H, Jochems A, Lambin P, Horsch D. Results and adverse events of personalized peptide receptor radionuclide therapy with 90Yttrium and 177Lutetium in 1048 patients with neuroendocrine neoplasms. Oncotarget 2018; 9: 16932-50.
  3. Begum NJ, Thieme A, Eberhardt N, Tauber R, D'Alessandria C, Beer AJ, Glatting G, Eiber M, Kletting P. The Effect of Total Tumor Volume on the Biologically Effective Dose to Tumor and Kidneys for Lu-177-Labeled PSMA Peptides. J Nucl Med 2018; 59: 929-33.
  4. Brehmer S, Guthier CV, Clausen S, Schneider F, Schulte DM, Benker M, Bludau F, Glatting G, Marx A, Schmiedek P, Hesser J, Wenz F, Giordano FA. Combined stereotactic biopsy and stepping-source interstitial irradiation of glioblastoma multiforme. J Neurosurg Sci 2018; 62: 214-20.
  5. Breitkreutz F, Patt M, Solbach C. Die erlaubnisfreie Herstellung und Anwendung patienten-individualisierter Arzneimittel. Der Nuklearmediziner 2018; 41: 360-68.
  6. Cihoric N, Badra EV, Tsikkinis A, Prasad V, Kroeze S, Igrutinovic I, Jeremic B, Beck M, Zschaeck S, Wust P, Ghadjar P. Clinical trials involving positron emission tomography and prostate cancer: an analysis of the ClinicalTrials. gov database. Radiat Oncol 2018; 13: 9.
  7. Exner S, Prasad V, Wiedenmann B, Grotzinger C. Octreotide Does Not Inhibit Proliferation in Five Neuroendocrine Tumor Cell Lines. Front Endocrinol 2018; 9: 10.
  8. Gastroenterologie DGf. [Practice guideline neuroendocrine tumors - AWMF-Reg. 021-27]. Z Gastroenterol 2018; 56: 583-681.
  9. Gear JI, Cox MG, Gustafsson J, Gleisner KS, Murray I, Glatting G, Konijnenberg M, Flux GD. EANM practical guidance on uncertainty analysis for molecular radiotherapy absorbed dose calculations. Eur J Nucl Med Mol Imaging 2018; 45: 2456-74.
  10. Huang K, Brenner W, Prasad V. Tumor lysis syndrome: a rare, but serious complication of radioligand therapies. J Nucl Med 2018.
  11. Janssen JC, Meissner S, Woythal N, Prasad V, Brenner W, Diederichs G, Hamm B, Makowski MR. Comparison of hybrid 68Ga-PSMA-PET/CT and 99mTc-DPD-SPECT/CT for the detection of bone metastases in prostate cancer patients: Additional value of morphologic information from low dose CT. Eur Radiol 2018; 28: 610-9.
  12. Jimenez-Franco LD, Kletting P, Beer AJ, Glatting G. Treatment planning algorithm for peptide receptor radionuclide therapy considering multiple tumor lesions and organs at risk. Med Phys 2018; 45: 3516-23.
  13. Kletting P, Glatting G. Pharmakokinetische Modellierung in der Nuklearmedizin. Der Nuklearmediziner 2018; 41: 52-60.
  14. Kotzerke J, Böhmer D, Schlomm T, Maurer T, Beer AJ, Schmidberger H. PSMA-PET/CT has to be performed in every patient with biochemical recurrence following radical prostatectomy for early tumor detection. Nuklearmedizin 2018; 57: 69-73.
  15. Kretz D, Hesser J, Glatting G, Diehl S, Wenz F, He W, Zheng L. Modeling sphere dynamics in blood vessels for SIRT pre-planning - To fathom the potential and limitations. Z Med Phys 2018.
  16. Lassmann M, Glatting G. Dosimetrie für die Nuklearmedizinische Therapie. Der Nuklearmediziner 2018; 41: 11-2.
  17. Lisson CS, Lisson CG, Flosdorf K, Mayer-Steinacker R, Schultheiss M, von Baer A, Barth TFE, Beer AJ, Baumhauer M, Meier R, Beer M, Schmidt SA. Diagnostic value of MRI-based 3D texture analysis for tissue characterisation and discrimination of low-grade chondrosarcoma from enchondroma: a pilot study. Eur Radiol 2018; 28: 468-77.
  18. Miksch J, Thamm R, Solbach C, Bolenz C, Wiegel T, Krohn T, Prasad V, Beer AJ. 68Gallium-PSMA-11-PET/CT changes external beam radiation therapy concept even in low PSA-recurrences up to 0,5ng/ml. Eur J Nucl Med Mol Imaging 2018; 45: S527-S.
  19. Oliveira F, Leuzy A, Castelhano J, Chiotis K, Hasselbalch SG, Rinne J, Mendonca A, Otto M, Lleo A, Santana I, Johansson J, Anderl-Straub S, Arnim C, Beer A, Blesa R, Fortea J, Sanna-Kaisa H, Portelius E, Pannee J, Zetterberg H, Blennow K, Moreira AP, Abrunhosa A, Nordberg A, Castelo-Branco M. Data driven diagnostic classification in Alzheimer's disease based on different reference regions for normalization of PiB-PET images and correlation with CSF concentrations of A beta species. Neuroimage Clin 2018; 20: 603-10.
  20. Pala A, Reske SN, Eberhardt N, Scheuerle A, Konig R, Schmitz B, Beer AJ, Wirtz CR, Coburger J. Diagnostic accuracy of intraoperative perfusion-weighted MRI and 5-aminolevulinic acid in relation to contrast-enhanced intraoperative MRI and 11C-methionine positron emission tomography in resection of glioblastoma: a prospective study. Neurosurg Rev 2018.
  21. Plöckinger U, Prasad V, Ziagaki A, Tiling N, Poellinger A. 2-deoxy-2- 18 fluoro-D-glucosePET/CT 18FDG PET/CT may not be a viable biomarker in Pompe disease. Hum Genomics 2018; 12: 9.
  22. Rodriguez Laval V, Pavel M, Steffen IG, Baur AD, Dilz LM, Fischer C, Detjen K, Prasad V, Pascher A, Geisel D, Denecke T. Mesenteric Fibrosis in Midgut Neuroendocrine Tumors: Functionality and Radiological Features. Neuroendocrinology 2018; 106: 139-47.
  23. Solbach C. Radiochemie in Klinik und Praxis. Der Nuklearmediziner 2018; 41: 287-88.
  24. Solbach C, Patt M. PET-Liganden für die Diagnostik der Alzheimer-Demenz: Amyloid und Tau. Der Nuklearmediziner 2018; 41: 310-16.
  25. Stolzenburg A, Lückerath K, Samnick S, Speer M, Kneer K, Schmid JS, Grigoleit G, Hofmann S, Beer AJ, Bunjes D, Knop S, Buck AK, Einsele H, Lapa C. Prognostic value of F-18 FDG-PET/CT in multiple myeloma patients before and after allogeneic hematopoietic cell transplantation. Eur J Nucl Med Mol Imaging 2018; 45: 1694-704.
  26. Wieder H, Beer AJ, Siveke J, Schuster T, Buck AK, Herrmann K, Stollfuss JC. 18F-fluorothymidine PET for predicting survival in patients with resectable pancreatic cancer. Oncotarget 2018; 9: 10128-34.
  27. Woythal N, Arsenic R, Kempkensteffen C, Miller K, Janssen J-C, Huang K, Makowski MR, Brenner W, Prasad V. Immunohistochemical Validation of PSMA Expression Measured by 68Ga-PSMA PET/CT in Primary Prostate Cancer. J Nucl Med 2018; 59: 238-43.